Investors

Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company employing epigenetics – a novel way to control gene expression – to overcome the problem of resistance seen with current oncology treatments. We are focused on the development and commercialization of our lead product candidate, entinostat, an epigenetic therapy for treatment-resistant cancers.

NASDAQ: SNDX
$ 9.03 -0.40 (4.24%)
Day High: 9.51
Day Low:  9.00
Volume:    39,239
4:00 PM ET
12.08.16

Delayed ~20 min., by eSignal.

Press Releases


Events & Presentations